DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS
Top Cited Papers
- 1 May 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Retina
- Vol. 31 (5), 915-923
- https://doi.org/10.1097/iae.0b013e318206d18c
Abstract
To evaluate the safety and efficacy of Ozurdex (dexamethasone intravitreal implant) 0.7 mg in the treatment of diabetic macular edema in vitrectomized eyes. This was a prospective, multicenter, open-label, 26-week study. Fifty-five patients with treatment-resistant diabetic macular edema and a history of previous pars plana vitrectomy in the study eye received a single intravitreal injection of 0.7-mg dexamethasone intravitreal implant. The primary efficacy outcome measure was the change in central retinal thickness from baseline to Week 26 measured by optical coherence tomography. The mean age of patients was 62 years. The mean duration of diabetic macular edema was 43 months. The mean (95% confidence interval) change from baseline central retinal thickness (403 μm) was -156 μm (-190, -122 μm) at Week 8 (P < 0.001) and -39 μm (-65, -13 μm) at Week 26 (P = 0.004). The mean (95% CI) increase in best-corrected visual acuity from baseline (54.5 letters) was 6.0 letters (3.9, 8.1 letters) at Week 8 (P < 0.001) and 3.0 letters (0.1, 6.0 letters) at Week 26 (P = 0.046). At Week 8, 30.4% of patients had gained ≥10 letters in best-corrected visual acuity. Conjunctival hemorrhage, conjunctival hyperemia, eye pain, and increased intraocular pressure were the most common adverse events. Treatment with dexamethasone intravitreal implant led to statistically and clinically significant improvements in both vision and vascular leakage from diabetic macular edema in difficult-to-treat vitrectomized eyes and had an acceptable safety profile.This publication has 22 references indexed in Scilit:
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010
- Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) StudyOphthalmology, 2009
- Analysis of the Effect of Intravitreal Bevacizumab Injection on Diabetic Macular Edema after Cataract SurgeryOphthalmology, 2009
- EVALUATION OF THE SAFETY AND PERFORMANCE OF AN APPLICATOR FOR A NOVEL INTRAVITREAL DEXAMETHASONE DRUG DELIVERY SYSTEM FOR THE TREATMENT OF MACULAR EDEMARetina, 2009
- Physiology of vitreous surgeryAlbrecht von Graefes Archiv für Ophthalmologie, 2008
- LONG-TERM EFFECT OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN PATIENTS WITH CHRONIC DIFFUSE DIABETIC MACULAR EDEMARetina, 2008
- Bevacizumab (Avastin) for Diabetic Macular Edema in Previously Vitrectomized EyesAmerican Journal of Ophthalmology, 2007
- DIFFERENCE IN CLEARANCE OF INTRAVITREAL TRIAMCINOLONE ACETONIDE BETWEEN VITRECTOMIZED AND NONVITRECTOMIZED EYESRetina, 2005
- Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injectionOphthalmology, 2003
- The Clearance of Intravitreal Triamcinolone AcetonideAmerican Journal of Ophthalmology, 1982